<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4423</id>
  <title>T3D4369</title>
  <common-name>L-Tryptophan</common-name>
  <description>Tryptophan is an essential amino acid which is the precursor of serotonin. Serotonin is a brain neurotransmitter, platelet clotting factor and neurohormone found in organs throughout the body. Metabolism of tryptophan to serotonin requires nutrients such as vitamin B6, niacin and glutathione. Niacin is an important metabolite of tryptophan. High corn or other tryptophan-deficient diets can cause pellagra, which is a niacin-tryptophan deficiency disease with symptoms of dermatitis, diarrhea and dementia. Inborn errors of tryptophan metabolism exist where a tumor (carcinoid) makes excess serotonin. Hartnup's disease is a disease where tryptophan and other amino acids are not absorbed properly. Tryptophan supplements may be useful in each condition, in carcinoid replacing the over-metabolized nutrient and in Hartnup's supplementing a malabsorbed nutrient. Some disorders of excess tryptophan in the blood may contribute to mental retardation. Assessment of tryptophan deficiency is done through studying excretion of tryptophan metabolites in the urine or blood. Blood may be the most sensitive test because the amino acid tryptophan is transported in a unique way. Increased urination of tryptophan fragments correlates with increased tryptophan degradation, which occurs with oral contraception, depression, mental retardation, hypertension and anxiety states. The requirement for tryptophan and protein decreases with age. Adults' minimum daily requirement is 3 mg/kg/day or about 200 mg a day. This may be an underestimation, for there are 400 mg of tryptophan in just a cup of wheat germ. A cup of low fat cottage cheese contains 300 mg of tryptophan and chicken and turkey contain up to 600 mg per pound.</description>
  <cas>73-22-3</cas>
  <pubchem-id>6305</pubchem-id>
  <chemical-formula>C11H12N2O2</chemical-formula>
  <weight>204.22</weight>
  <appearance>White powder.</appearance>
  <melting-point>290.5 dec°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>1.34E+004 mg/L (at 25°C)</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure nil="true"/>
  <target nil="true"/>
  <mechanism-of-toxicity>A number of important side reactions occur during the catabolism of tryptophan on the pathway to acetoacetate. The first enzyme of the catabolic pathway is an iron porphyrin oxygenase that opens the indole ring. The latter enzyme is highly inducible, its concentration rising almost 10-fold on a diet high in tryptophan. Kynurenine is the first key branch point intermediate in the pathway. Kynurenine undergoes deamniation in a standard transamination reaction yielding kynurenic acid. Kynurenic acid and metabolites have been shown to act as antiexcitotoxics and anticonvulsives. A second side branch reaction produces anthranilic acid plus alanine. Another equivalent of alanine is produced further along the main catabolic pathway, and it is the production of these alanine residues that allows tryptophan to be classified among the glucogenic and ketogenic amino acids. The second important branch point converts kynurenine into 2-amino-3-carboxymuconic semialdehyde, which has two fates. The main flow of carbon elements from this intermediate is to glutarate. An important side reaction in liver is a transamination and several rearrangements to produce limited amounts of nicotinic acid, which leads to production of a small amount of NAD&lt;sup&gt;+&lt;/sup&gt; and NADP&lt;sup&gt;+&lt;/sup&gt;.</mechanism-of-toxicity>
  <metabolism>Hepatic.</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Tryptophan may be useful in increasing serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms>Symptoms of overdose include agitation, confusion, diarrhea, fever, overactive reflexes, poor coordination, restlessness, shivering, sweating, talking or acting with excitement you cannot control, trembling or shaking, twitching, and vomiting.</symptoms>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:35:45Z</created-at>
  <updated-at type="dateTime">2026-04-17T18:55:29Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Kalma</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00078</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>16828</chebi-id>
  <biocyc-id>TRP</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB00150</drugbank-id>
  <pdb-id>TRP</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O</moldb-smiles>
  <moldb-formula>C11H12N2O2</moldb-formula>
  <moldb-inchi>InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1</moldb-inchi>
  <moldb-inchikey>QIVBCDIJIAJPQS-VIFPVBQESA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">204.2252</moldb-average-mass>
  <moldb-mono-mass type="decimal">204.089877638</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-1.06</logp>
  <hmdb-id>HMDB00929</hmdb-id>
  <chembl-id>CHEMBL54976</chembl-id>
  <chemspider-id>6066</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Sten Vilhelm Gatenbeck, Per Olof Hedman, &amp;#8220;Fermentative process for the production of L-tryptophan and its derivatives.&amp;#8221; U.S. Patent US3963572, issued April, 1974.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003329</chemdb-id>
  <dsstox-id>DTXSID5021419</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00003513</susdat-id>
  <iupac>(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid</iupac>
</compound>
